Thrissur Elite Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.80 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 45.61%
- Profit Growth -55.01%
- Ebitda -37.57%
- Net Worth 4.84%
- Total Assets 21.50%
About Thrissur Elite Drugs
Thrissur Elite Drugs Private Limited (TEDPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 March 2016 (Eight years and 11 months 25 days old ). Its registered office is in Thrissur, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Mohandas Kunhandy and Kollara Prakasan serve as directors at the Company.
Company Details
- Location
Thrissur, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909KL2016PTC040292
- Company No.
040292
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Thrissur Elite Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohandas Kunhandy  | Managing Director | 02-Mar-2016 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kollara Prakasan | Director | 02-Mar-2016 | Current |
Financial Performance of Thrissur Elite Drugs.
Thrissur Elite Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 45.61% increase. The company also saw a substantial fall in profitability, with a 55.01% decrease in profit. The company's net worth moved up by a moderate rise of 4.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Thrissur Elite Drugs?
In 2021, Thrissur Elite Drugs had a promoter holding of 18.50% and a public holding of 81.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Guruvijaya Kuri Company LimitedKollara Prakasan is a mutual person
- Malabartrogon Valley Private Limited
Kollara Prakasan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Thrissur Elite Drugs?
Thrissur Elite Drugs has a workforce of 3 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Thrissur Elite Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Thrissur Elite Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.